AI Article Synopsis

  • The balance of Th1 and Th2 lymphocytes in the lungs varies with diseases like idiopathic pulmonary fibrosis (IPF) and collagen vascular diseases (CVD) during interstitial pneumonia (IP) progression.
  • Research showed that IPF patients exhibit a lower CD4(+)/CD8(+) ratio and present a Th2 dominance, while CVD patients display Th1 dominance during active IP, as indicated by serum KL-6 levels.
  • Understanding the Th1/Th2 profile in active IP cases could guide targeted Th1/Th2 modulator therapies, despite elevated KL-6 in both conditions.

Article Abstract

The balance between CD4(+) T helper (Th1) lymphocytes producing interferon-gamma or Interleukin-4 (Th2) in the lungs may vary among diseases and during the progression of interstitial pneumonia (IP). Both idiopathic pulmonary fibrosis (IPF) and collagen vascular diseases (CVD) are associated with IP, but the clinical course and the response to treatment are different. Since Th1 or Th2 modulating drugs have been proven to alter the lymphocyte balance in vitro, it is important to elucidate the Th1/Th2 profile in patients with active IP. Bronchoalveolar lavage (BAL) was performed in patients who had IPF (n = 12) or CVD (n = 12) with IP, as well as in patients who had bronchoectasis and bronchopneumonia (n = 12). The CVD patients had rheumatoid arthritis (n = 6), Sjogren's syndrome (n = 2), dermatomyositis (n = 1), progressive systemic sclerosis (n = 2), and CREST syndrome (n = 1) as the underlying diseases. IP activity was evaluated by measuring serum KL-6, which is a clinically useful indicator for IP. The Th1/ Th2 balance and the CD4(+)/CD8(+) ratio were determined for lymphocytes obtained from BAL by flow cytometric analysis. In IPF patients, the CD4(+)/CD8(+) ratio was lower than in CVD patients. IPF patients showed Th2 dominance and CVD patients showed Th1 dominance when IP was active as evaluated by the serum KL-6 level. These data indicated that the Th1/Th2 balance of CD4(+) T cells in the BAL differs between active IPF and CVD, even though KL-6 is elevated in both diseases. Therefore, the Th1/Th2 profile should be investigated to determine the use of Th1/Th2 modulator therapy for active IP with elevation of KL-6.

Download full-text PDF

Source
http://dx.doi.org/10.1080/08923970600809389DOI Listing

Publication Analysis

Top Keywords

serum kl-6
12
cvd patients
12
patients
9
th1/th2 balance
8
cd4+ cells
8
patients active
8
interstitial pneumonia
8
evaluated serum
8
balance cd4+
8
th1/th2 profile
8

Similar Publications

Objectives: Rituximab is emerging as a promising therapeutic option for systemic sclerosis-associated interstitial lung disease (SSc-ILD). However, little is known about factors that predict the efficacy of rituximab in SSc-ILD.

Methods: A post-hoc analysis was performed on prospective data from 48 patients with SSc-ILD in the double-blind, randomized, placebo-controlled DESIRES trial.

View Article and Find Full Text PDF

Objectives: To clarify the impact of sarilumab (SAR) on the progression of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA).

Methods: We conducted a retrospective review of all consecutive RA patients from the KEIO-RA cohort who visited our institution between 2018 and 2024 and received SAR treatment. Patients were followed for 24 months from the initiation of SAR.

View Article and Find Full Text PDF

Background: This study investigated poor prognostic factors for the relapse of interstitial lung disease (ILD) in patients with microscopic polyangiitis (MPA) after remission induction therapy.

Methods: We enrolled patients diagnosed with MPA complicated by ILD according to the Chapel Hill Consensus definition from 2001 to 2023 in multiple institutions in the REVEAL cohort. All patients who were treated with immunosuppressive therapy were followed up, and those who relapsed with ILD were extracted in this study.

View Article and Find Full Text PDF

AIE nanoparticle with enhanced fluorescence for ultrasensitive lateral flow immunoassays and point-of-care diagnosis of interstitial lung disease.

Biosens Bioelectron

March 2025

School of Science and Engineering, Shenzhen Institute of Aggregate Science and Technology, The Chinese University of Hong Kong, Shenzhen, (CUHK-Shenzhen), Guangdong, 518172, China.

Krebs von den Lungen-6 (KL-6) has been recognized as an effective serum biomarker for interstitial lung disease (ILD). The KL-6 accurate detection is of great significance for evaluating the severity of ILD and the prognosis of patients. In this study, a bright aggregation-induced emission luminogen (AIEgen) N, N'-((1,2-diphenylethene-1,2-diyl)bis(4,1-phenylene))bis(N-phenylnaphthalen-1-amine) (TPETN) with a high quantum yield of 87.

View Article and Find Full Text PDF

Background: Despite the autoimmune nature of psoriasis, the potential association between psoriasis and interstitial lung disease (ILD) remains underexplored. This study aimed to investigate the frequency and clinical features of ILD in patients with psoriasis and propose a new conceptual framework of "ILD associated with psoriasis".

Methods: A retrospective analysis of 117 patients with psoriasis was conducted, excluding those without chest imaging prior to methotrexate or biologic use and those with other comorbidities leading to ILD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!